The IMA Group announced its acquisition of Albuquerque Neuroscience, Inc., a clinical research site specializing in diseases of the central nervous system and general medical conditions, though financial terms remain private.
Albuquerque Neuroscience joins IMA’s Clinical Research Division, which specializes in Phase II-IV clinical trials in all therapeutic areas including Alzheimer’s Disease, vascular dementia, insomnia, pain management, fibromyalgia, constipation and sexual dysfunction.
“Albuquerque Neuroscience brings important new capabilities and expands the geographic footprint of our growing Clinical Research Division" Mark Weinberger, PhD, MPH and president of The IMA Group, said in a press release. "Their expertise in psychiatry, Alzheimer’s Disease and other neuropathic diseases, as well as their diverse patient population, strengthens and extends our current clinical research offerings.”
Albuquerque Neuroscience will continue to operate under its current name and will retain key leadership and staff members.
The IMA Group provides clinical evaluation and screening services to employers, payers and government agencies, in addition to clinical research services to pharmaceutical sponsors and CROs, according to the company's official website. The company's goal is to improve the quality of evaluations. It is interested in partnering with companies driven by technology.
The IMA Group has existed for more than 30 years.
